ResMed : Q3 2024 ResMed Earnings Results Webcast Corporate 1-Pager

A global leader in digital health

At ResMed, we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of- hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries.

140+

COUNTRIES SERVED

24.5M+

CLOUD-CONNECTABLE

DEVICES

174M+

Diversified revenue by business and by geography (LTM 3Q24)

53% Devices

34% Masks & Other

13% OOH SaaS

57% U.S., Canada, and

Latin America

30% Europe, Asia,

and Other

13% U.S. SaaS

Revenue	Non-GAAP	Non-GAAP
($B)	Operating Income ($B)	EPS
13%	15%	15%
CAGR	CAGR	CAGR
$4.6	$1.4	$7.24

$2.5

$0.7$3.65

LTM	LTM	LTM	LTM	LTM	LTM
3Q19	3Q24	3Q19	3Q24	3Q19	3Q24

LIVES CHANGED,

LAST 12 MONTHS

18B+

NIGHTS OF MEDICAL SLEEP

& RESPIRATORY DATA

~6%

REINVESTED IN R&D

9,700+

PATENTS AND DESIGNS

(9)%1-yr

5%3-yr

Mick Farrell named	Named one of America's top 500	Named one of the "Management
#1 Health Technology	"Most Responsible Companies"	Top 250" companies in (2020,
CEO of 2022	in (2021, 2022, 2023, 2024)	2021, 2022, 2023); top 25 among
		healthcare companies

99%5-yr

TOTAL SHAREHOLDER RETURN

(as of March 31, 2024)

Sleep health

~936 million people live with sleep apnea - the upper airway closes off causing the body to jolt "awake" to take breaths throughout the night.1

~870 million people live with insomnia.2

ResMed provides: CPAP therapy that's smaller, quieter, more comfortable, and more connected

• and in Germany, a reimbursed Digital Health Application (DiGA) for insomnia.

• 39% lower all-cause mortality rate when treating sleep apnea with CPAP3

• 87% patient adherence on CPAP therapy when remotely and self monitored4

85-90% OF COPD CASES ARE CAUSED BY CIGARETTE SMOKING8

SaaS

More people want to age in place and receive affordable, high-qualitycare outside the hospital.

US Market

77% with obesity5

76% with heart failure6

72% with type 2 diabetes7

ALSO HAVE SLEEP APNEA

COPD/asthma/lung disease

An estimated 480 million people live with chronic obstructive pulmonary disease,9 the world's third leading killer.10

Over 330 million people live with asthma.11

ResMed provides:The world's most complete digital solution suite throughout a patient's journey.

• 76% reduced risk of one-year death for COPD patients using non-invasiveventilation (NIV)12

Propeller Health's Digital Therapeutic Platform resulted in:

• 58% higher medication adherence13
• 57% fewer asthma-related emergency visits and hospitalizations14
• 35% fewer COPD-related emergency visits and hospitalizations15

ResMed provides: Comprehensive cloud-based clinical, financial, and operational solutions that support healthcare providers across a range of care settings outside of the hospital.

German Market

Home medical	Home	Home	Hospice	Skilled	Life plan	Senior	Private
equipment	infusion	health		nursing	communities	living	duty
(HME) providers	pharmacy			facilities

Ambulant	Stationär	Youth &	Outpatient	Non-
(Similar to	(Similar to	diabled care	therapy	professional
US home	US nursing			care
health)	homes)

Contact

Media: [e-mail] Investors: [e-mail]

1 Benjafield AV et al. Lancet Respir Med 2019 2 ResMed internal estimate. 3 Pepin JL et al. Chest 2022 4 Malhotra A et al. Chest 2018 5 O'Keeffe T and Patterson EJ. Obes Surg 2004 6 Olden- burg O et al. Eur J Heart Fail 2007 7 Einhorn D et al. Endocr Pract 2007 8 Amer Lung Assoc https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd/what-causes-copd. Accessed Jun 19, 2020. 9 Boers E et al. ERJ Suppl (ERS Congress late-breaking abstract) 2022 10 WHO. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed Jun 19, 2020. 11 The Global Asthma Report 2018. http://globalasthmareport.org/burden/burden.php. Accessed April 26, 2022. 12 Kohnlein T et al. Lancet Respir Med 2014 13 Van Sickle D et al. Eur Resp J 2016 14 Merchant R et al. World Allergy Organ J 2018 15 Brazeal T et al. Abstract at European Respiratory Society 2021

Distributed by ResMed Corp, 9001 Spectrum Center Boulevard, San Diego, CA 92123 USA. [phone] or [phone](toll-free). See ResMed.com for other ResMed locations worldwide. Specifications may change without notice. For patent and other intellectual property information, see ResMed.com/ip. © 2024 ResMed. Updated: April 25, 2024.